Screening to identify people who may qualify for Alzheimer's disease clinical programs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pre‑screening process used to determine who might qualify for Roche-sponsored Phase 3 interventional Alzheimer's disease trials. Potential participants provide recent memory complaint history and informant reports and typically complete brief cognitive testing and a medical history review. The process excludes people who are dependent in basic activities of daily living due to cognitive impairment, have other neurologic disorders that could explain cognitive decline, severe CNS trauma, or other serious medical conditions, and accommodates eyeglasses and hearing aids for testing. Pre‑screening is performed at participating clinical sites to create a pool of candidates for subsequent interventional studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
* Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study

Exclusion Criteria:

* Dependency in basic activities of daily living (bADLs) due to cognitive impairment
* Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
* Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
* History of severe, clinically significant central nervous system trauma
* Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
* For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting
• Banner Alzheimer?s Institute
  Phoenix, Arizona, United States Recruiting
• Banner Sun Health Research Institute
  Sun City, Arizona, United States Recruiting
• Sun Valley Research Center, Inc.
  Imperial, California, United States Recruiting
• Irvine Center for Clinical Research
  Irvine, California, United States Recruiting
• Healthy Brain Clinic
  Long Beach, California, United States Recruiting

+184 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Reference Study ID Number: WP45722 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• FAME: A Italian test to recognize famous faces and name them

  This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.

  Recruiting at 8 sites Istituti Clinici Scientifici Maugeri SpA · Sciacca, AG and 9 other locations · NCT07911878

• NMS-01 safety test in people with mild to moderate Alzheimer's disease

  This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.

  Recruiting Neumous Inc. · Seoul, Seodaemun · NCT07869238

• Choose Myself (Before) Losing Myself

  We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07846566

• Lecanemab-irmb in Real-World Use for Alzheimer’s Disease

  This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.

  Recruiting Eisai Inc. · Nutley, New Jersey · NCT07821658

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.